Full text
PDFImages in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bloche M. Gregg. Race-based therapeutics. N Engl J Med. 2004 Nov 8;351(20):2035–2037. doi: 10.1056/NEJMp048271. [DOI] [PubMed] [Google Scholar]
- Carson P., Ziesche S., Johnson G., Cohn J. N. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999 Sep;5(3):178–187. doi: 10.1016/s1071-9164(99)90001-5. [DOI] [PubMed] [Google Scholar]
- Meadows Michelle. FDA approves heart drug for black patients. FDA Consum. 2005 Sep-Oct;39(5):8–9. [PubMed] [Google Scholar]
- Moran Andrew E., Cooper Richard S. Isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2005 Mar 10;352(10):1041–1043. doi: 10.1056/NEJM200503103521018. [DOI] [PubMed] [Google Scholar]
- Taylor Anne L., Ziesche Susan, Yancy Clyde, Carson Peter, D'Agostino Ralph, Jr, Ferdinand Keith, Taylor Malcolm, Adams Kirkwood, Sabolinski Michael, Worcel Manuel. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004 Nov 8;351(20):2049–2057. doi: 10.1056/NEJMoa042934. [DOI] [PubMed] [Google Scholar]
- Wood A. J. Racial differences in the response to drugs--pointers to genetic differences. N Engl J Med. 2001 May 3;344(18):1394–1396. doi: 10.1056/NEJM200105033441811. [DOI] [PubMed] [Google Scholar]